Inovio Pharmaceuticals Regulatory Approval
The FDA granted accelerated approval for INOVIO's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). This represents the first U.S. FDA-approved DNA medicine and validates INOVIO's platform technology, with a commercial launch expected in Q1 2027.
“With the approval of VOCERYQ, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option. VOCERYQ is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer